Abstract
Chimeric antigen receptor (CAR) T-cells, engineered autologous T-cells that target antigens found in leukemia, have shown durable remissions in relapsed acute lymphoblastic leukemia (ALL). Infant ALL with KMT2A rearrangements (KMT2Ar) is a rare, aggressive form of leukemia associated with extramedullary disease both at diagnosis and at relapse, and overall outcomes for these patients are dismal. Here we report the successful use of tisagenlecleucel, a CAR T-cell product approved for relapsed/refractory ALL, in a patient with KMT2Ar infant ALL who was treated for combined marrow and extramedullary (renal) relapse.
Keywords:
ALL; ALL relapse; immunotherapy; pediatric hematology/oncology.
© 2020 Wiley Periodicals LLC.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Marrow Neoplasms / pathology
-
Bone Marrow Neoplasms / therapy*
-
Combined Modality Therapy
-
Female
-
Hematopoietic Stem Cell Transplantation
-
Histone-Lysine N-Methyltransferase / genetics
-
Humans
-
Immunotherapy, Adoptive / methods*
-
Infant
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / therapy*
-
Mutation
-
Myeloid-Lymphoid Leukemia Protein / genetics
-
Neoplasm Recurrence, Local / genetics
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Recurrence, Local / therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
-
Prognosis
-
Receptors, Chimeric Antigen / immunology*
Substances
-
KMT2A protein, human
-
Receptors, Chimeric Antigen
-
Myeloid-Lymphoid Leukemia Protein
-
Histone-Lysine N-Methyltransferase